Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LFCR | PRESS-RELEASE | neutral | 4/10 | Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manufacture engineering | Mar 4, 2026 |
| AQST | PRESS-RELEASE | mixed | 6/10 | Aquestive Therapeutics reported mixed Q4 and full-year 2025 results, with 10% quarterly revenue growth to $13.0M but a 3 | Mar 4, 2026 |
| KROS | PRESS-RELEASE | mixed | 6/10 | Keros Therapeutics reported a net income of $87.0 million for 2025, a significant improvement from a $187.4 million net | Mar 4, 2026 |
| MAIA | PRESS-RELEASE | neutral | 5/10 | MAIA Biotechnology closed an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million i | Mar 4, 2026 |
| CANF | PRESS-RELEASE | neutral | 5/10 | Can-Fite BioPharma is facilitating the immediate cash exercise of existing warrants to purchase 795,869 ADSs at a reduce | Mar 4, 2026 |
| CDT | PRESS-RELEASE | mixed | 6/10 | CDT Equity Inc. announced the acquisition of a 20% equity stake in Sarborg for $115 million, paid via stock and pre-fund | Mar 4, 2026 |
| BCAX | PRESS-RELEASE | neutral | 3/10 | Bicara Therapeutics granted a stock option to purchase 115,000 shares to a new employee as an inducement to employment, | Mar 4, 2026 |
| OCGN | PRESS-RELEASE | mixed | 6/10 | Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider net loss, while highl | Mar 4, 2026 |
| CTMX | PRESS-RELEASE | neutral | 3/10 | CytomX Therapeutics announced it will report full year 2025 financial results on March 16, 2026, before markets open, fo | Mar 4, 2026 |
| DYAI | PRESS-RELEASE | neutral | 4/10 | Dyadic International and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-fr | Mar 4, 2026 |
| CLRB | PRESS-RELEASE | mixed | 6/10 | Cellectar Biosciences reported its 2025 financial results, showing a significantly reduced net loss of $21.8M compared t | Mar 4, 2026 |
| FENC | PRESS-RELEASE | neutral | 4/10 | Fennec Pharmaceuticals announced that Tampa General Hospital (TGH) Cancer Institute is initiating a real-world study eva | Mar 4, 2026 |
| TCRX | PRESS-RELEASE | bullish | 7/10 | TScan Therapeutics reported financial results for Q4 and full-year 2025, highlighted by a 268% year-over-year increase i | Mar 4, 2026 |
| CANF | PRESS-RELEASE | mixed | 6/10 | Can-Fite BioPharma announced positive safety results from its Phase IIa trial of namodenoson in advanced pancreatic canc | Mar 4, 2026 |
| KALA | PRESS-RELEASE | mixed | 6/10 | KALA BIO announced a strategic initiative to become a dedicated AI infrastructure provider for the biotech industry by d | Mar 4, 2026 |
| HCM | PRESS-RELEASE | neutral | 5/10 | HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC) | Mar 4, 2026 |
| ALVO | PRESS-RELEASE | neutral | 3/10 | Alvotech announced it will release its Q4 and full-year 2025 financial and operating results on March 18, 2026, followed | Mar 4, 2026 |
| ETON | PRESS-RELEASE | neutral | 3/10 | Eton Pharmaceuticals announced it will report its fourth quarter and full year 2025 financial results on March 19, 2026, | Mar 3, 2026 |
| PRQR | PRESS-RELEASE | neutral | 3/10 | ProQR Therapeutics announced that its management will present at the Citizens Life Sciences Conference on March 11, 2026 | Mar 3, 2026 |
| ANAB | PRESS-RELEASE | bullish | 8/10 | AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestone | Mar 3, 2026 |
| SANA | PRESS-RELEASE | bullish | 8/10 | Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical and operational progr | Mar 3, 2026 |
| OCS | PRESS-RELEASE | mixed | 7/10 | Oculis reported its 2025 financial results and clinical progress, highlighting a strong cash position of $268.7 million, | Mar 3, 2026 |
| VXRT | PRESS-RELEASE | neutral | 3/10 | Vaxart, Inc. announced upcoming webcast events to discuss its full-year 2025 financial results and provide a stockholder | Mar 3, 2026 |
| LODE | PRESS-RELEASE | neutral | 4/10 | Comstock Inc. announced progress in commissioning its first industry-scale solar panel recycling facility in Silver Spri | Mar 3, 2026 |
| NBP | PRESS-RELEASE | neutral | 5/10 | NovaBridge Biosciences announced an upcoming virtual call to present Phase 2a clinical data for VIS-101, a bispecific in | Mar 3, 2026 |
| PPCB | PRESS-RELEASE | mixed | 6/10 | Propanc Biopharma highlighted preclinical and early compassionate-use data for its lead asset PRP, a proenzyme therapy t | Mar 3, 2026 |
| ADIL | PRESS-RELEASE | bullish | 7/10 | Adial Pharmaceuticals announced a collaboration framework with Molteni Farmaceutici for the potential European commercia | Mar 3, 2026 |
| PRME | PRESS-RELEASE | mixed | 6/10 | Prime Medicine reported its full-year 2025 financial results and provided a business update, highlighting progress in it | Mar 3, 2026 |
| COLL | PRESS-RELEASE | neutral | 3/10 | Collegium Pharmaceutical announced a partnership with Paris Hilton on a public awareness campaign called 'Embrace Your S | Mar 3, 2026 |
| RNTX | PRESS-RELEASE | neutral | 5/10 | Rein Therapeutics has dosed the first patient in its Phase 2 clinical trial for LTI-03, an inhaled therapy targeting idi | Mar 3, 2026 |